Upcoming Dividend • 9h
Upcoming dividend of ₫800 per share Eligible shareholders must have bought the stock before 09 July 2026. Payment date: 20 July 2026. The company last paid an ordinary dividend in September 2016. The average dividend yield among industry peers is 3.7%. New Risk • Jun 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Vietnamese stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.2% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.1% average weekly change). Market cap is less than US$100m (₫1.49t market cap, or US$56.7m). Reported Earnings • Mar 28
Full year 2025 earnings released: EPS: ₫1,538 (vs ₫1,474 in FY 2024) Full year 2025 results: EPS: ₫1,538 (up from ₫1,474 in FY 2024). Revenue: ₫1.12t (up 16% from FY 2024). Net income: ₫98.5b (up 4.3% from FY 2024). Profit margin: 8.8% (in line with FY 2024). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. Announcement • Feb 13
OPC Pharmaceutical Joint Stock Company, Annual General Meeting, Apr 25, 2026 OPC Pharmaceutical Joint Stock Company, Annual General Meeting, Apr 25, 2026. Location: hall of opc pharmaceutical jsc, 1017 hong bang street, phu lam ward, ho chi minh Vietnam Reported Earnings • Oct 30
Third quarter 2025 earnings released: EPS: ₫331 (vs ₫354 in 3Q 2024) Third quarter 2025 results: EPS: ₫331. Revenue: ₫272.8b (up 41% from 3Q 2024). Net income: ₫32.5b (up 43% from 3Q 2024). Profit margin: 12% (in line with 3Q 2024). Reported Earnings • Jul 30
Second quarter 2025 earnings released: EPS: ₫252 (vs ₫379 in 2Q 2024) Second quarter 2025 results: EPS: ₫252 (down from ₫379 in 2Q 2024). Revenue: ₫237.0b (up 9.8% from 2Q 2024). Net income: ₫21.9b (down 9.8% from 2Q 2024). Profit margin: 9.2% (down from 11% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. Announcement • Mar 07
OPC Pharmaceutical Joint Stock Company, Annual General Meeting, Apr 26, 2025 OPC Pharmaceutical Joint Stock Company, Annual General Meeting, Apr 26, 2025. Location: hall of opc pharmaceutical, joint stock company, no. 1017 hong bang, ward 12, district 6, ho chi minh Vietnam Reported Earnings • Oct 24
Third quarter 2024 earnings released: EPS: ₫232 (vs ₫497 in 3Q 2023) Third quarter 2024 results: EPS: ₫232 (down from ₫497 in 3Q 2023). Revenue: ₫194.0b (down 13% from 3Q 2023). Net income: ₫22.7b (down 29% from 3Q 2023). Profit margin: 12% (down from 14% in 3Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has remained flat, which means it is well ahead of earnings. Reported Earnings • May 08
First quarter 2024 earnings released: EPS: ₫424 (vs ₫452 in 1Q 2023) First quarter 2024 results: EPS: ₫424. Revenue: ₫221.2b (up 12% from 1Q 2023). Net income: ₫32.0b (up 10% from 1Q 2023). Profit margin: 14% (in line with 1Q 2023). Declared Dividend • May 06
Final dividend of ₫1,500 announced Shareholders will receive a dividend of ₫1,500. Ex-date: 13th May 2024 Payment date: 21st May 2024 Dividend yield will be 6.0%, which is higher than the industry average of 3.7%. Sustainability & Growth Dividend is well covered by both earnings (28% earnings payout ratio) and cash flows (39% cash payout ratio). The dividend has increased by an average of 8.5% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 2.9% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Announcement • Mar 12
OPC Pharmaceutical Joint Stock Company, Annual General Meeting, Apr 27, 2024 OPC Pharmaceutical Joint Stock Company, Annual General Meeting, Apr 27, 2024. Location: Venue: No.1017 Hong Bang street ward 12, district 6 HCMC Vietnam Reported Earnings • Nov 05
Third quarter 2023 earnings released: EPS: ₫330 (vs ₫588 in 3Q 2022) Third quarter 2023 results: EPS: ₫330 (down from ₫588 in 3Q 2022). Revenue: ₫222.5b (down 20% from 3Q 2022). Net income: ₫31.8b (down 15% from 3Q 2022). Profit margin: 14% (in line with 3Q 2022). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 03
Second quarter 2023 earnings released: EPS: ₫583 (vs ₫448 in 2Q 2022) Second quarter 2023 results: EPS: ₫583 (up from ₫448 in 2Q 2022). Revenue: ₫278.5b (up 30% from 2Q 2022). Net income: ₫37.4b (up 30% from 2Q 2022). Profit margin: 13% (in line with 2Q 2022). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Announcement • May 26
OPC Pharmaceutical Joint Stock Company Announces the Resignation of Le Van Son as Chairman of the BOD On April 27, 2023, OPC Pharmaceutical Joint Stock Company announced the resignation letter of Mr. Le Van Son as Chairman of the BOD. Upcoming Dividend • May 10
Upcoming dividend of ₫500 per share at 5.3% yield Eligible shareholders must have bought the stock before 17 May 2023. Payment date: 25 May 2023. Trailing yield: 5.3%. Lower than top quartile of Vietnamese dividend payers (9.0%). Higher than average of industry peers (3.6%). Announcement • May 09
OPC Pharmaceutical Joint Stock Company Announces the Remaining Cash Dividend in 2023, Payable on May 25, 2023 On March 28, 2023, OPC Pharmaceutical Joint Stock Company announced the record date to pay the remaining cash dividend in 2023 as follows: Record date: May 18, 2023; Exercise ratio: 5%/share (500 dong/share); Payment time: May 25, 2023. Announcement • May 06
Opc Pharmaceutical Joint Stock Company Announces Executive Changes Opc Pharmaceutical Joint Stock Company announced resignation of Le Van Son as Chairman of the BOD, Nguyen Hai Duong as Member of the BOD, Nguyen Trung Thanh as Member of the Supervisory Board and appointment of Hoang Le Son as Chairman of the BOD, Pham Thi Xuan Huong as Member of the BOD cum General Director, Nguyen Anh Vu as Member of the Supervisory Board. Reported Earnings • Apr 30
First quarter 2023 earnings released First quarter 2023 results: Revenue: ₫198.1b (down 48% from 1Q 2022). Net income: ₫29.1b (down 28% from 1Q 2022). Profit margin: 15% (up from 11% in 1Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Upcoming Dividend • Apr 12
Upcoming dividend of ₫1,000 per share at 5.2% yield Eligible shareholders must have bought the stock before 19 April 2023. Payment date: 26 April 2023. Trailing yield: 5.2%. Lower than top quartile of Vietnamese dividend payers (8.9%). Higher than average of industry peers (4.1%). Buying Opportunity • Jan 30
Now 21% undervalued Over the last 90 days, the stock is up 9.7%. The fair value is estimated to be ₫32,283, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.6% over the last 3 years. Earnings per share has grown by 20%. Reported Earnings • Jan 28
Full year 2022 earnings released: EPS: ₫2,214 (vs ₫1,968 in FY 2021) Full year 2022 results: EPS: ₫2,214 (up from ₫1,968 in FY 2021). Revenue: ₫1.17t (up 4.3% from FY 2021). Net income: ₫142.2b (up 13% from FY 2021). Profit margin: 12% (in line with FY 2021). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth. Announcement • Dec 23
OPC Pharmaceutical Joint Stock Company Appoints Phuong Thanh Nhung as Deputy Chairman of the Board of Director OPC Pharmaceutical Joint Stock Company appointed Mrs. Phuong Thanh Nhung as Deputy Chairman of the BOD. Mrs. Phuong Thanh Nhung's former position in the organization was as a member of the BOD. Effective date of the appointment is December 20, 2022. Valuation Update With 7 Day Price Move • Dec 19
Investor sentiment improved over the past week After last week's 17% share price gain to ₫27,400, the stock trades at a trailing P/E ratio of 11.5x. Average trailing P/E is 13x in the Pharmaceuticals industry in Vietnam. Total returns to shareholders of 66% over the past three years. Announcement • Nov 18
OPC Pharmaceutical Joint Stock Company Appoints Duong Minh Hung as Deputy CEO OPC Pharmaceutical Joint Stock Company announced the change in personnel as follows: Appointment: Mr. Duong Minh Hung - Former position in the organization: - Newly appointed position: Deputy CEO - Term: 03 years - Effective date: November 15, 2022. Board Change • Nov 16
No independent directors There are 7 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 7 new directors. 1 experienced director. No highly experienced directors. No independent directors (5 non-independent directors). Chairman Son Le is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. Reported Earnings • Nov 02
Third quarter 2022 earnings released: EPS: ₫588 (vs ₫541 in 3Q 2021) Third quarter 2022 results: EPS: ₫588 (up from ₫541 in 3Q 2021). Revenue: ₫278.4b (down 6.6% from 3Q 2021). Net income: ₫37.6b (up 8.6% from 3Q 2021). Profit margin: 14% (up from 12% in 3Q 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Reported Earnings • Jul 26
Second quarter 2022 earnings released Second quarter 2022 results: Revenue: ₫214.1b (up 10% from 2Q 2021). Net income: ₫28.7b (up 60% from 2Q 2021). Profit margin: 13% (up from 9.2% in 2Q 2021). The increase in margin was driven by higher revenue. Valuation Update With 7 Day Price Move • Jul 20
Investor sentiment deteriorated over the past week After last week's 58% share price decline to ₫25,269, the stock trades at a trailing P/E ratio of 5.2x. Average trailing P/E is 15x in the Pharmaceuticals industry in Vietnam. Total loss to shareholders of 39% over the past three years. Board Change • Apr 27
No independent directors There are 7 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 7 new directors. 1 experienced director. No highly experienced directors. No independent directors (5 non-independent directors). Supervisory Board Member Thanh Nguyen is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. Reported Earnings • Mar 11
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: ₫4,742 (up from ₫3,567 in FY 2020). Revenue: ₫1.12t (up 16% from FY 2020). Net income: ₫126.0b (up 33% from FY 2020). Profit margin: 11% (up from 9.8% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Reported Earnings • Feb 02
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: ₫4,742 (up from ₫3,969 in FY 2020). Revenue: ₫1.12t (up 16% from FY 2020). Net income: ₫126.4b (up 20% from FY 2020). Profit margin: 11% (in line with FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • Dec 13
Upcoming dividend of ₫1,000 per share Eligible shareholders must have bought the stock before 20 December 2021. Payment date: 28 December 2021. Payout ratio is a comfortable 42% but the company is paying out more than the cash it is generating. Trailing yield: 5.3%. Lower than top quartile of Vietnamese dividend payers (6.3%). Higher than average of industry peers (3.2%). Reported Earnings • Oct 22
Third quarter 2021 earnings released The company reported a solid third quarter result with improved earnings and revenues, although profit margins were flat. Third quarter 2021 results: Revenue: ₫298.2b (up 40% from 3Q 2020). Net income: ₫34.6b (up 51% from 3Q 2020). Profit margin: 12% (in line with 3Q 2020). Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 7% per year. Reported Earnings • Jul 26
Second quarter 2021 earnings released: EPS ₫675 (vs ₫1,022 in 2Q 2020) The company reported a poor second quarter result with weaker earnings and profit margins, although revenues were flat. Second quarter 2021 results: Revenue: ₫194.4b (flat on 2Q 2020). Net income: ₫17.9b (down 34% from 2Q 2020). Profit margin: 9.2% (down from 14% in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 7% per year. Upcoming Dividend • Jun 05
Upcoming dividend of ₫2,000 per share Eligible shareholders must have bought the stock before 11 June 2021. Payment date: 21 June 2021. Trailing yield: 4.5%. Lower than top quartile of Vietnamese dividend payers (7.7%). Higher than average of industry peers (3.9%). Reported Earnings • Mar 19
Full year 2020 earnings released: EPS ₫3,969 (vs ₫3,401 in FY 2019) The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: ₫965.6b (down 2.4% from FY 2019). Net income: ₫105.5b (up 17% from FY 2019). Profit margin: 11% (up from 9.1% in FY 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 3% per year. Valuation Update With 7 Day Price Move • Feb 03
Investor sentiment improved over the past week After last week's 19% share price gain to ₫68,800, the stock is trading at a trailing P/E ratio of 17.3x, up from the previous P/E ratio of 14.5x. This compares to an average P/E of 16x in the Pharmaceuticals industry in Vietnam. Total returns to shareholders over the past three years are 41%. Is New 90 Day High Low • Jan 29
New 90-day high: ₫65,500 The company is up 15% from its price of ₫57,000 on 30 October 2020. The Vietnamese market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 2.0% over the same period. Reported Earnings • Jan 22
Full year 2020 earnings released: EPS ₫3,969 The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: ₫965.7b (down 2.4% from FY 2019). Net income: ₫105.8b (up 17% from FY 2019). Profit margin: 11% (up from 9.1% in FY 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 2% per year. Is New 90 Day High Low • Dec 25
New 90-day high: ₫62,900 The company is up 12% from its price of ₫56,000 on 24 September 2020. The Vietnamese market is up 16% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 5.0% over the same period. Is New 90 Day High Low • Nov 17
New 90-day high: ₫58,000 The company is up 2.0% from its price of ₫56,800 on 19 August 2020. The Vietnamese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 6.0% over the same period. Is New 90 Day High Low • Nov 02
New 90-day high: ₫57,300 The company is up 1.0% from its price of ₫56,900 on 03 August 2020. The Vietnamese market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 7.0% over the same period. Reported Earnings • Oct 22
Third quarter earnings released Over the last 12 months the company has reported total profits of ₫90.4b, down 7.9% from the prior year. Total revenue was ₫906.6b over the last 12 months, down 11% from the prior year. Is New 90 Day High Low • Oct 08
New 90-day low: ₫54,100 The company is down 5.0% from its price of ₫56,900 on 10 July 2020. The Vietnamese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 8.0% over the same period. 
